Co-Diagnostics, Inc. announced a reverse stock split at a ratio of 1-for-30 shares to regain Nasdaq compliance.
The reverse stock split will be effective on January 2, 2026, under the symbol "CODX".
Shareholders approved the reverse stock split at a Special Meeting on December 5, 2025.
Reverse Stock Split
Co-Diagnostics implemented a 1-for-30 reverse stock split to meet the Nasdaq minimum bid price requirement.
Shareholder Approval
The reverse stock split was approved by stockholders at a meeting on December 5, 2025.
Effect on Stockholders
All existing shares of common stock will be combined into one share post the reverse stock split.
- The reverse stock split aims to maintain compliance with The Nasdaq Capital Market requirements.
- Existing shares will be consolidated, impacting stock options and warrants holders.
The reverse stock split is a strategic move by Co-Diagnostics to ensure compliance and strengthen its position in the market.